FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807600632> ?p ?o ?g. }

• W2807600632 endingPage "1831" @default.
• W2807600632 startingPage "1819" @default.
• W2807600632 abstract "Long-term safety of tiotropium/olodaterol RespimatReg in patients with moderate-to-very severe COPD and renal impairment in the TONADOReg studies Craig LaForce,1 Eric Derom,2 Ulrich Bothner,3 Isabel M Kloer,3 Matthias Trampisch,4 Roland Buhl5 1NC Clinical Research, Raleigh, NC, USA; 2Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; 3Pharmacovigilance, Boehringer Ingelheim International GmbH, Ingelheim, Germany; 4Biostatistics & Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 5Pulmonary Department, Mainz University Hospital, Mainz, Germany Introduction: The safety, lung function efficacy, and symptomatic benefits of combined tiotropium and olodaterol in patients with COPD were established in the 1-year TONADO® studies (NCT01431274; NCT01431287). As tiotropium is predominantly excreted by the kidneys, the long-term safety profile of tiotropium/olodaterol was investigated in patients with renal impairment in a prespecified safety analysis of the TONADO studies. Methods: These were 2 replicate, randomized, double-blind, parallel-group, 52-week Phase III studies that assessed tiotropium/olodaterol compared with tiotropium or olodaterol alone (all via Respimat®) in patients with moderate-to-very severe COPD. In this analysis, renal impairment was defined as mild (creatinine clearance [CLcr] 60–89 mL/min), moderate (CLcr 30–59 mL/min) or severe (CLcr 15–29 mL/min). Adverse events (AEs) were pooled from both studies. Results: Of 3,041 patients included in this analysis, 1,333 (43.8%) had mild, 404 (13.3%) had moderate, and 5 (0.2%) had severe renal impairment; these were distributed equally between treatment groups. Almost one-quarter of all treated patients (23.4%) had a history of cardiac disorder, 45.6% had hypertension, and 13.3% had glucose metabolism disorders, including diabetes. AEs with olodaterol, tiotropium, and tiotropium/olodaterol occurred in 75.1%, 70.8%, and 72.0% of patients with no renal impairment, 75.7%, 74.0%, and 73.3% with mild renal impairment, and 84.3%, 79.5%, and 79.7% with moderate renal impairment, respectively. There was no notable effect of renal impairment on the proportion of patients with an AE, and no differences were observed between tiotropium/olodaterol versus the monocomponents. There was no difference in the incidence of major adverse cardiac events, renal and urinary tract AEs, or potential anticholinergic effects with increasing severity of renal impairment. Conclusion: Over half the patients enrolled in the TONADO studies had renal impairment, and there was a high level of pre-existing cardiovascular comorbidity. The safety and tolerability of tiotropium/olodaterol is comparable to the monocomponents, irrespective of the level of renal impairment. Keywords: COPD, renal impairment, comorbidities, tiotropium, olodaterol, safety" @default.
• W2807600632 created "2018-06-13" @default.
• W2807600632 creator A5009000391 @default.
• W2807600632 creator A5036109929 @default.
• W2807600632 creator A5039635841 @default.
• W2807600632 creator A5053912202 @default.
• W2807600632 creator A5082448702 @default.
• W2807600632 creator A5082911997 @default.
• W2807600632 date "2018-06-01" @default.
• W2807600632 modified "2023-09-25" @default.
• W2807600632 title "Long-term safety of tiotropium/olodaterol Respimat^® in patients with moderate-to-very severe COPD and renal impairment in the TONADO^® studies" @default.
• W2807600632 cites W1490958657 @default.
• W2807600632 cites W1543718713 @default.
• W2807600632 cites W1550111394 @default.
• W2807600632 cites W1826636375 @default.
• W2807600632 cites W1878842323 @default.
• W2807600632 cites W1952327193 @default.
• W2807600632 cites W1999370028 @default.
• W2807600632 cites W2003693083 @default.
• W2807600632 cites W2007789292 @default.
• W2807600632 cites W2015963390 @default.
• W2807600632 cites W2038697731 @default.
• W2807600632 cites W2043383132 @default.
• W2807600632 cites W2044458860 @default.
• W2807600632 cites W2049258903 @default.
• W2807600632 cites W2060873423 @default.
• W2807600632 cites W2082198827 @default.
• W2807600632 cites W2088763762 @default.
• W2807600632 cites W2094849850 @default.
• W2807600632 cites W2096698825 @default.
• W2807600632 cites W2125836178 @default.
• W2807600632 cites W2128643475 @default.
• W2807600632 cites W2135563121 @default.
• W2807600632 cites W2140370548 @default.
• W2807600632 cites W2141034778 @default.
• W2807600632 cites W2147703657 @default.
• W2807600632 cites W2153441442 @default.
• W2807600632 cites W2156758490 @default.
• W2807600632 cites W2162865421 @default.
• W2807600632 cites W2165834413 @default.
• W2807600632 cites W2169278962 @default.
• W2807600632 cites W2169709108 @default.
• W2807600632 cites W2288098251 @default.
• W2807600632 cites W2302016179 @default.
• W2807600632 cites W2544555580 @default.
• W2807600632 cites W2553006813 @default.
• W2807600632 cites W4254423821 @default.
• W2807600632 doi "https://doi.org/10.2147/copd.s161489" @default.
• W2807600632 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5987861" @default.
• W2807600632 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29910611" @default.
• W2807600632 hasPublicationYear "2018" @default.
• W2807600632 type Work @default.
• W2807600632 sameAs 2807600632 @default.
• W2807600632 citedByCount "6" @default.
• W2807600632 countsByYear W28076006322018 @default.
• W2807600632 countsByYear W28076006322019 @default.
• W2807600632 countsByYear W28076006322020 @default.
• W2807600632 countsByYear W28076006322021 @default.
• W2807600632 crossrefType "journal-article" @default.
• W2807600632 hasAuthorship W2807600632A5009000391 @default.
• W2807600632 hasAuthorship W2807600632A5036109929 @default.
• W2807600632 hasAuthorship W2807600632A5039635841 @default.
• W2807600632 hasAuthorship W2807600632A5053912202 @default.
• W2807600632 hasAuthorship W2807600632A5082448702 @default.
• W2807600632 hasAuthorship W2807600632A5082911997 @default.
• W2807600632 hasBestOaLocation W28076006321 @default.
• W2807600632 hasConcept C126322002 @default.
• W2807600632 hasConcept C159641895 @default.
• W2807600632 hasConcept C197934379 @default.
• W2807600632 hasConcept C2776780178 @default.
• W2807600632 hasConcept C2776968687 @default.
• W2807600632 hasConcept C2777714996 @default.
• W2807600632 hasConcept C3018587741 @default.
• W2807600632 hasConcept C42219234 @default.
• W2807600632 hasConcept C71924100 @default.
• W2807600632 hasConceptScore W2807600632C126322002 @default.
• W2807600632 hasConceptScore W2807600632C159641895 @default.
• W2807600632 hasConceptScore W2807600632C197934379 @default.
• W2807600632 hasConceptScore W2807600632C2776780178 @default.
• W2807600632 hasConceptScore W2807600632C2776968687 @default.
• W2807600632 hasConceptScore W2807600632C2777714996 @default.
• W2807600632 hasConceptScore W2807600632C3018587741 @default.
• W2807600632 hasConceptScore W2807600632C42219234 @default.
• W2807600632 hasConceptScore W2807600632C71924100 @default.
• W2807600632 hasLocation W28076006321 @default.
• W2807600632 hasLocation W28076006322 @default.
• W2807600632 hasLocation W28076006323 @default.
• W2807600632 hasLocation W28076006324 @default.
• W2807600632 hasLocation W28076006325 @default.
• W2807600632 hasLocation W28076006326 @default.
• W2807600632 hasOpenAccess W2807600632 @default.
• W2807600632 hasPrimaryLocation W28076006321 @default.
• W2807600632 hasRelatedWork W1194826699 @default.
• W2807600632 hasRelatedWork W1879798697 @default.
• W2807600632 hasRelatedWork W1928394001 @default.
• W2807600632 hasRelatedWork W1979115310 @default.
• W2807600632 hasRelatedWork W2168449172 @default.
• W2807600632 hasRelatedWork W2362299873 @default.

• next